Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.

Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I.

Clin Colorectal Cancer. 2018 Sep 29. pii: S1533-0028(18)30219-6. doi: 10.1016/j.clcc.2018.09.010. [Epub ahead of print]

PMID:
30404764
2.

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.

Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR.

Oncogene. 2018 Oct 23. doi: 10.1038/s41388-018-0554-z. [Epub ahead of print]

PMID:
30353166
3.

Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends.

Edwards P, Davidson M, Calamai V, Cunningham D, Starling N.

Cancer Treat Rev. 2018 Dec;71:32-38. doi: 10.1016/j.ctrv.2018.10.009. Epub 2018 Oct 17. Review.

PMID:
30343173
4.

Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.

Athauda A, Watkins D, Mohammed K, Chau I, Starling N, Rao S, Tait D, Aitken K, Cunningham D.

Anticancer Res. 2018 Oct;38(10):5943-5949. doi: 10.21873/anticanres.12940.

PMID:
30275223
5.

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Damavandi MD, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N.

Cancer Discov. 2018 Oct;8(10):1270-1285. doi: 10.1158/2159-8290.CD-17-0891. Epub 2018 Aug 30.

PMID:
30166348
6.

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B, Fenwick K, Herman B, Matthews N, O'Leary B, Hulkki S, Gonzalez De Castro D, Patel A, Wotherspoon A, Okachi A, Rana I, Begum R, Davies MN, Powles T, von Loga K, Hubank M, Turner N, Watkins D, Chau I, Cunningham D, Lise S, Starling N, Gerlinger M.

Clin Chem. 2018 Nov;64(11):1626-1635. doi: 10.1373/clinchem.2018.289629. Epub 2018 Aug 27.

7.

The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.

Flynn M, Young K, Cunningham D, Starling N.

Ther Adv Med Oncol. 2018 Jul 11;10:1758835918786228. doi: 10.1177/1758835918786228. eCollection 2018. Review.

8.

Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.

Davidson M, Cafferkey C, Goode EF, Kouvelakis K, Hughes D, Reguera P, Kalaitzaki E, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N.

Clin Colorectal Cancer. 2018 Sep;17(3):223-230. doi: 10.1016/j.clcc.2018.05.014. Epub 2018 Jun 8.

PMID:
29980492
9.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

10.

Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.

Khakoo S, Georgiou A, Gerlinger M, Cunningham D, Starling N.

Crit Rev Oncol Hematol. 2018 Feb;122:72-82. doi: 10.1016/j.critrevonc.2017.12.002. Epub 2017 Dec 16. Review.

PMID:
29458792
11.

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Moorcraft SY, Gonzalez de Castro D, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M, Begum R, Eltahir Z, Wotherspoon A, Teixeira Mendes LS, Hulkki Wilson S, Gillbanks A, Baratelli C, Fotiadis N, Patel A, Braconi C, Valeri N, Gerlinger M, Rao S, Watkins D, Chau I, Starling N.

Ann Oncol. 2018 Jan 1;29(1):230-236. doi: 10.1093/annonc/mdx631.

PMID:
29361134
12.

Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.

Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, Shepherd S, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N.

Clin Colorectal Cancer. 2018 Mar;17(1):e69-e76. doi: 10.1016/j.clcc.2017.10.006. Epub 2017 Oct 16.

PMID:
29129559
13.

Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.

Moorcraft SY, Jones T, Walker BA, Ladas G, Kalaitzaki E, Yuan L, Begum R, Eltahir Z, Wotherspoon A, Montero-Fernandez A, Teixeira Mendes LS, Gonzalez de Castro D, Wilson SH, Proszek P, To YM, Hawkes E, Roy A, Cunningham D, Rao S, Watkins D, Starling N, Bowcock AM, Chau I.

Oncotarget. 2017 Apr 11;8(39):64999-65008. doi: 10.18632/oncotarget.17048. eCollection 2017 Sep 12.

14.

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.

Davidson M, Chau I, Cunningham D, Khabra K, Iveson T, Hickish T, Seymour M, Starling N.

World J Gastrointest Oncol. 2017 Aug 15;9(8):333-340. doi: 10.4251/wjgo.v9.i8.333.

15.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.

Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi MD, Lote H, Rana I, Williams A, Eccles SA, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, Valeri N.

Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8.

16.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T.

Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19.

PMID:
28527133
17.

Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.

Sclafani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, Morano F, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I.

Oncologist. 2017 Jun;22(6):728-736. doi: 10.1634/theoncologist.2016-0396. Epub 2017 May 5.

18.

Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.

Kipps E, Young K, Starling N.

Ther Adv Med Oncol. 2017 Mar;9(3):159-170. doi: 10.1177/1758834016688816. Epub 2017 Mar 1. Review.

19.

Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.

Sclafani F, Morano F, Cunningham D, Baratelli C, Kalaitzaki E, Watkins D, Starling N, Chau I, Rao S.

Oncologist. 2017 Apr;22(4):402-408. doi: 10.1634/theoncologist.2016-0241. Epub 2017 Feb 16.

20.

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.

Davidson M, Starling N.

Onco Targets Ther. 2016 Nov 25;9:7235-7245. eCollection 2016. Review.

21.

Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies.

Moorcraft SY, Begum R, Cunningham D, Peckitt C, Baratelli C, Gillbanks A, Rogers P, Nwokorie V, Chau I, Watkins D, Starling N.

Clin Colorectal Cancer. 2017 Sep;16(3):e181-e189. doi: 10.1016/j.clcc.2016.09.008. Epub 2016 Oct 6.

PMID:
27839727
22.

Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.

Khan K, Athauda A, Aitken K, Cunningham D, Watkins D, Starling N, Cook GJ, Kalaitzaki E, Chau I, Rao S.

Oncologist. 2016 Dec;21(12):1502-1508. Epub 2016 Oct 14.

23.

Targeting deficient DNA damage repair in gastric cancer.

Young K, Starling N, Cunningham D.

Expert Opin Pharmacother. 2016 Sep;17(13):1757-66. doi: 10.1080/14656566.2016.1217992. Epub 2016 Aug 8. Review.

PMID:
27488684
24.

Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma.

Tarazona N, Smyth EC, Peckit C, Chau I, Watkins D, Rao S, Starling N, Cunningham D.

Ther Adv Med Oncol. 2016 Mar;8(2):104-12. doi: 10.1177/1758834015621669.

25.

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study.

Moorcraft SY, Fontana E, Cunningham D, Peckitt C, Waddell T, Smyth EC, Allum W, Thompson J, Rao S, Watkins D, Starling N, Chau I.

BMC Cancer. 2016 Feb 17;16:112. doi: 10.1186/s12885-016-2145-0.

26.

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.

Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I.

Oncotarget. 2016 Mar 15;7(11):12672-81. doi: 10.18632/oncotarget.7208.

27.

Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.

Grenader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D, Bridgewater J.

Ann Oncol. 2016 Apr;27(4):687-92. doi: 10.1093/annonc/mdw012. Epub 2016 Jan 19.

PMID:
26787231
28.

Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey.

Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, Watkins D, Rao S.

Trials. 2016 Jan 9;17:17. doi: 10.1186/s13063-015-1105-3.

29.

Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.

Fontana E, Smyth EC, Cunningham D, Rao S, Watkins D, Allum WH, Thompson J, Waddell T, Peckitt C, Chau I, Starling N.

Gastric Cancer. 2016 Oct;19(4):1114-24. doi: 10.1007/s10120-015-0561-5. Epub 2015 Nov 5.

PMID:
26541768
30.

Current and Future Therapies for Advanced Gastric Cancer.

Davidson M, Okines AF, Starling N.

Clin Colorectal Cancer. 2015 Dec;14(4):239-50. doi: 10.1016/j.clcc.2015.05.013. Epub 2015 Jun 6. Review.

PMID:
26524924
31.

Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.

Sclafani F, Iyer R, Cunningham D, Starling N.

Crit Rev Oncol Hematol. 2015 Sep;95(3):318-36. doi: 10.1016/j.critrevonc.2015.03.008. Epub 2015 Apr 15. Review.

PMID:
25921418
32.

Pancreatic neuroendocrine tumors: a review.

Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N.

Future Oncol. 2015;11(5):853-64. doi: 10.2217/fon.14.285. Review.

PMID:
25757686
33.

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.

Khan K, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, Jain V, Trivedi S, Stanway S, Cunningham D, Chau I.

BMC Cancer. 2015 Jan 21;15:15. doi: 10.1186/s12885-015-1014-6.

34.

A case of Takotsubo syndrome following 5-fluorouracil chemotherapy.

Knott K, Starling N, Rasheed S, Foran J, Cafferkey C, Rosen S, Nicholson A, Baksi J, Lyon A.

Int J Cardiol. 2014 Dec 15;177(2):e65-7. doi: 10.1016/j.ijcard.2014.09.154. Epub 2014 Oct 13. No abstract available.

PMID:
25449494
35.

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.

Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M.

Ann Oncol. 2015 Mar;26(3):463-76. doi: 10.1093/annonc/mdu253. Epub 2014 Jul 11. Review.

PMID:
25015334
36.

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.

Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I.

Eur J Cancer. 2014 May;50(8):1422-9. doi: 10.1016/j.ejca.2014.02.003. Epub 2014 Mar 6.

PMID:
24613126
37.

Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit.

Khan K, Ang JE, Starling N, Sclafani F, Shah K, Judson I, Molife LR, Banerji U, de Bono JS, Cunningham D, Kaye SB.

Gastric Cancer. 2014 Oct;17(4):621-629. doi: 10.1007/s10120-013-0328-9. Epub 2014 Jan 21.

38.

The genomic landscape of oesophagogastric junctional adenocarcinoma.

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A.

J Pathol. 2013 Nov;231(3):301-10.

PMID:
24308032
39.

A student leadership model for promoting educational programs in organ donation and transplantation.

Reville P, Zhao C, Perez T, Nowacki AS, Phillips D, Bowen G, Starling N, Pflaum B, Strickland R, Fung J, Askar M.

Transplant Proc. 2013 May;45(4):1287-94. doi: 10.1016/j.transproceed.2013.01.074.

PMID:
23726553
40.

A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.

Starling N, Hawkes EA, Chau I, Watkins D, Thomas J, Webb J, Brown G, Thomas K, Barbachano Y, Oates J, Cunningham D.

Ann Oncol. 2012 Apr;23(4):942-7. doi: 10.1093/annonc/mdr317. Epub 2011 Jul 12.

PMID:
21750117
41.

Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience.

Waddell T, Kotsori A, Constantinidou A, Yousaf N, Ashley S, Parton M, Allen M, Starling N, Papadopoulos P, O'Brien M, Smith I, Johnston S.

Br J Cancer. 2011 May 24;104(11):1675-9. doi: 10.1038/bjc.2011.138. Epub 2011 Apr 26.

42.

A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.

Starling N, Vázquez-Mazón F, Cunningham D, Chau I, Tabernero J, Ramos FJ, Iveson TJ, Saunders MP, Aranda E, Countouriotis AM, Ruiz-Garcia A, Wei G, Tursi JM, Guillen-Ponce C, Carrato A.

Ann Oncol. 2012 Jan;23(1):119-27. doi: 10.1093/annonc/mdr046. Epub 2011 Mar 29.

PMID:
21447616
43.

Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.

Barton S, Starling N, Swanton C.

Curr Cancer Drug Targets. 2010 Dec;10(8):799-812. Review.

PMID:
20718710
44.

The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer.

Myerson JS, Faria A, Puglisi M, Starling N, Popat S, O'Brien ME.

Lung Cancer. 2010 Sep;69(3):365-6. doi: 10.1016/j.lungcan.2010.06.017. No abstract available.

PMID:
20655614
45.

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, Valladares-Ayerbes M, Wilke H, Archer C, Kurek R, Beadman C, Oates J.

Ann Oncol. 2010 Nov;21(11):2213-9. doi: 10.1093/annonc/mdq247. Epub 2010 May 23.

PMID:
20497967
46.

Colorectal cancer.

Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N.

Lancet. 2010 Mar 20;375(9719):1030-47. doi: 10.1016/S0140-6736(10)60353-4. Review.

PMID:
20304247
47.

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.

Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I.

J Clin Oncol. 2009 Nov 20;27(33):5499-505. doi: 10.1200/JCO.2008.21.5384. Epub 2009 Oct 26.

PMID:
19858399
48.

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.

Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I.

Br J Cancer. 2009 Jun 2;100(11):1725-30. doi: 10.1038/sj.bjc.6605070. Epub 2009 May 12.

49.

Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.

Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR.

J Clin Oncol. 2009 Aug 10;27(23):3786-93. doi: 10.1200/JCO.2008.19.4274. Epub 2009 Apr 27.

PMID:
19398575
50.

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.

Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A.

Br J Cancer. 2008 Sep 16;99(6):868-74. doi: 10.1038/sj.bjc.6604622.

Supplemental Content

Loading ...
Support Center